Metis Techbio-p (7666) Fundamentals 2026 — Revenue Analysis | SniperIQ
Metis Techbio-p (7666) is a CN-listed Healthcare company in Biotechnology with a market capitalization of HK
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Metis Techbio-p's market cap?
Metis Techbio-p (7666) has a market capitalization of approximately HK
What is Metis Techbio-p's P/E ratio?
Metis Techbio-p's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 10.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Metis Techbio-p?
Metis Techbio-p runs a net profit margin of -373.2%, a gross margin of 66.0%, and an operating margin of -367.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Metis Techbio-p generate?
Metis Techbio-p reported revenue of
Does Metis Techbio-p pay a dividend?
Metis Techbio-p does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Metis Techbio-p financially healthy?
Metis Techbio-p carries a debt-to-equity ratio of 0.13x and a current ratio of 6.67x, with a market beta of 0.00. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Metis Techbio-p a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Metis Techbio-p (7666) the key facts are: market cap HK
Track Metis Techbio-p's full fundamentals live
Get Metis Techbio-p's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.